Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03829410 |
| Title | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Trovagene, Inc. |
| Indications | |
| Therapies |
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Mayo Clinic Cancer Center | Recruiting | Phoenix | Arizona | 85054 | United States | Details |
| CARTI Cancer Center | Recruiting | Little Rock | Arkansas | 72205 | United States | Details |
| USC Norris Comprehensive Cancer Center | Recruiting | Los Angeles | California | 90033 | United States | Details |
| Mayo Clinic Florida | Recruiting | Jacksonville | Florida | 32224 | United States | Details |
| University of Kansas Medical Center Research Institute | Recruiting | Kansas City | Kansas | 66160 | United States | Details |
| Mayo Clinic Rochester | Recruiting | Rochester | Minnesota | 55905 | United States | Details |
| Inova Schar Cancer Institute | Recruiting | Fairfax | Virginia | 22031 | United States | Details |